Immunoglobulin G4 related disease

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
1 Unique IMPs
3 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune, humanized) 1 substance
Phase III: 2 Phase II: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

2 trials
  • Horizon Therapeutics Ireland Designated Activity Company Commercial
    IMP not specified
    2023-508290-81-00 6 countries 2020 n=90
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2025-521398-15-00 8 countries 2025 n=50
    Recruiting

Phase II

1 trial
  • Amgen Inc. Commercial
    INEBILIZUMAB
    2025-520988-41-00 4 countries 2026 n=7
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 1 Phase II 1
Horizon Therapeutics Ireland Designated Activity Company Commercial 1 Phase III 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase III 1
New trials by year
2020
1
2025
1
2026
1
← All indication landscapes